医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vitruvias Therapeutics and Sunny Pharmtech Expand Partnership to Co-Develop Additional High Value Generic Drugs

2016年04月18日 PM07:57
このエントリーをはてなブックマークに追加


 

AUBURN, Ala. & TAIPEI, Taiwan

Sunny Pharmtech Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced today that they have signed two additional agreements to co-develop and market two additional high-value generic drugs. This will expand the original partnership agreement signed on April 2015, from four to five products, and adds a separate agreement which allows Vitruvias to buy in to a late stage, injectable project for $1.75 mil in upfront and milestone payments.

The addition of these two projects will strengthen the portfolios of both organizations by adding products in markets that currently exceed $600 mil dollars. Both projects are in the final stages of development with the first ANDA tentatively scheduled for filing in the second quarter of 2017.

“We are thrilled to have the opportunity to further partner with Sunny Pharmtech on projects as sophisticated as these,” said Carl Whatley, General Manager of Vitruvias. “They have proven themselves to be an innovation-engine with regards to difficult-to-develop generics, and we are very fortunate to have found a partner with such a high level of development expertise.”

Dr. Yon-Lian Wu, Sunny Pharmtech’s CEO and Chairperson, added, “I am delighted to announce the strengthening of the strategic partnership between Sunny Pharmtech and Vitruvias. These additional projects will allow us to address markets where the options for the patient are limited. We hope our eventual entry into these underserved markets will represent opportunities for patients who need these medicines, and our respective organizations.”

About Sunny Pharmtech Inc.

Sunny Pharmtech Inc. is an emerging specialty pharmaceutical company based in Taiwan and was founded in 2004 with a focus on the development of technically difficult products. In 2014, the capability of developing and producing active pharmaceutical ingredients was added. The resulting organization is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products which includes orals, liquids, semi-solids, and parenterals. www.sunnypharmtech.com/home/

About Vitruvias Therapeutics LLC

Vitruvias is an emerging specialty pharmaceutical company which develops, manufactures, and markets generic prescription products for the U.S. and Canadian markets. Founded in 2013, the privately-held company specializes in generic semi-solid and parenteral products. The current focus of the company is on the development of selective, high-value generic products with their first approval expected in 2017. www.vitruvias.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005007/en/

CONTACT

Vitruvias Therapeutics LLC
Carl Whatley, 334-329-5601
carl@vitruvias.com
or
Sunny
Pharmtech Inc.
Newman Pui, +886 22664-9600
newman.pui@sunnypharmtech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究